Silexion Therapeutics Corp. (NASDAQ:SLXN) released new preclinical data for SIL-204, its next-generation siRNA therapeutic candidate. SIL-204, administered in an extended-release formulation, reduced ...

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

Cayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi ...

In a report released on January 27, Naz Rahman from Maxim Group reiterated a Buy rating on Silexion Therapeutics (SLXN – Research Report), with ...

Silexion Therapeutics, known for its pioneering work in RNAi therapies, has previously achieved promising results in a Phase 2 trial with its first-generation product, LODER™, for non-resectable ...

Silexion Therapeutics Corp. announced promising preclinical results for its second-generation RNA interference therapy, SIL-204, which demonstrates synergistic efficacy when used in combination ...

On Tuesday, Silexion Therapeutics Corp. (NASDAQ:SLXN) released new preclinical data for SIL-204, its next-generation siRNA therapeutic candidate. SIL-204, administered in an extended-release ...